Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tederox versus Enhertu in high-risk HER2-positive early breast cancer
IRCT20250624066245N1Phase 3Not yet recruiting
- Sponsor
- Nano Daru
- Start
- Nov 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab deruxtecan in breast cancer (2 arms), sponsored by Nano Daru. Primary endpoint: Pathological complete response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20250624066245N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250624066245N1.